by Acute ischemic stroke (AIS) occurs due to lack of blood flow to brain caused by a blood clot blocking or plugging an artery. This leads to shortage of oxygen and nutrients to the brain cells causing cell damage or death. Signs and symptoms of AIS include sudden numbness or weakness, especially on one side of the body, sudden vision changes and trouble speaking or understanding speech. With timely treatment risk of long term disability or death due to AIS can be reduced. Thrombectomy and intravenous thrombolysis are medical treatments approved for AIS management which help recanalize blocked arteries and restore oxygenated blood flow to the brain.
The global Acute Ischemic Stroke market is estimated to be valued at US$ 12 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends witnessed in the AIS market is the emergence of minimally invasive treatments. Due to potential benefits such as reduced trauma, lower risk of infection and faster recovery, minimally invasive procedures are gaining popularity for AIS management. Advancements in catheter based technologies have enabled procedures like thrombectomy to be performed with minimal incisions, reducing hospital stay and improving outcomes. Growing research on imaging techniques to improve patient selection process for minimally invasive treatments is expected to further drive their adoption.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low for the AIS market due to the high costs involved in establishing manufacturing facilities and the requirement of extensive research and development.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are many established players providing treatment and diagnostic options for AIS.
Bargaining power of suppliers: The bargaining power of suppliers is also moderate as key raw materials suppliers are global pharma companies.
Threat of new substitutes: There is low threat from substitutes as currently there are limited treatment options available for AIS.
Competitive rivalry: The competitive rivalry in the market is high as key players are focusing on new product launches and innovation.
Key Takeaways
The Global Acute Ischemic Stroke (AIS) Market Size is expected to witness high growth over the forecast period of 2023-2030. The global Acute Ischemic Stroke market is estimated to be valued at US$ 12 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
North America is projected to dominate the regional segment during the forecast period owing to increasing incidence of stroke, developed healthcare infrastructure and presence of key market players in the region. This is attributed to increasing geriatric population which is more prone to strokes, increasing patient awareness regarding early diagnosis and treatment of strokes, and government initiatives to spread awareness.
Key players
Key players operating in the AIS market are Abbott Laboratories, Medtronic, Boston Scientific Corporation, Cordis Corporation, Genentech.
